Undertreatment of hypercholesterolaemia: a population-based study
AIMS: To assess the level of undertreatment of hypercholesterolaemia in the general population, taking intra-person variability in serum cholesterol concentrations into account, and to identify determinants of undertreatment of hypercholesterolaemia. METHODS: In this cross-sectional study, data from...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Blackwell Science Inc
2003
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1884230/ https://ncbi.nlm.nih.gov/pubmed/12680888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2003.01769.x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
pubmed-1884230 |
|---|---|
| record_format |
dspace |
| spelling |
pubmed-18842302008-01-14 Undertreatment of hypercholesterolaemia: a population-based study Mantel-Teeuwisse, A K Verschuren, W M M Klungel, O H Kromhout, D Lindemans, A D Avorn, J Porsius, A J de Boer, A Br J Clin Pharmacol Pharmacoepidemiology AIMS: To assess the level of undertreatment of hypercholesterolaemia in the general population, taking intra-person variability in serum cholesterol concentrations into account, and to identify determinants of undertreatment of hypercholesterolaemia. METHODS: In this cross-sectional study, data from two population-based surveys on cardiovascular disease risk factors conducted between 1987 and 1997 in the Netherlands were used. For all 64 757 respondents aged 20–59 years, treatment eligibility for lipid-lowering drug use was established according to the Dutch Cholesterol Consensus. Multivariate logistic models were used to identify determinants of undertreatment. RESULTS: During the study period, 56.8% of the study population had undesirable cholesterol concentrations (serum total cholesterol>5 mmol l(−1)) and 5.5% of those were eligible for pharmacological treatment based on their absolute risk of coronary heart disease. Of those eligible for pharmacological treatment, 16.3% were treated, and 19.6% of those treated had their serum total cholesterol concentration controlled. Only 3.2% of those eligible for pharmacological treatment were both treated and controlled. We identified several determinants for undertreatment, e.g. male gender and younger age for primary prevention and female gender and older age for secondary prevention. Treatment has improved slightly in more recent years. CONCLUSIONS: Over 95% of the population eligible for the pharmacological treatment of hypercholesterolaemia was either untreated or was uncontrolled. To decrease undertreatment, identification of high-risk patients should be increased. Those who are treated with lipid-lowering medication could further benefit from more aggressive treatment, especially with statins. Blackwell Science Inc 2003-04 /pmc/articles/PMC1884230/ /pubmed/12680888 http://dx.doi.org/10.1046/j.1365-2125.2003.01769.x Text en © 2003 Blackwell Publishing Ltd |
| institution |
US NLM |
| collection |
PubMed Central |
| language |
Inglês |
| format |
Artigo |
| topic |
Pharmacoepidemiology |
| spellingShingle |
Pharmacoepidemiology Mantel-Teeuwisse, A K Verschuren, W M M Klungel, O H Kromhout, D Lindemans, A D Avorn, J Porsius, A J de Boer, A Undertreatment of hypercholesterolaemia: a population-based study |
| description |
AIMS: To assess the level of undertreatment of hypercholesterolaemia in the general population, taking intra-person variability in serum cholesterol concentrations into account, and to identify determinants of undertreatment of hypercholesterolaemia. METHODS: In this cross-sectional study, data from two population-based surveys on cardiovascular disease risk factors conducted between 1987 and 1997 in the Netherlands were used. For all 64 757 respondents aged 20–59 years, treatment eligibility for lipid-lowering drug use was established according to the Dutch Cholesterol Consensus. Multivariate logistic models were used to identify determinants of undertreatment. RESULTS: During the study period, 56.8% of the study population had undesirable cholesterol concentrations (serum total cholesterol>5 mmol l(−1)) and 5.5% of those were eligible for pharmacological treatment based on their absolute risk of coronary heart disease. Of those eligible for pharmacological treatment, 16.3% were treated, and 19.6% of those treated had their serum total cholesterol concentration controlled. Only 3.2% of those eligible for pharmacological treatment were both treated and controlled. We identified several determinants for undertreatment, e.g. male gender and younger age for primary prevention and female gender and older age for secondary prevention. Treatment has improved slightly in more recent years. CONCLUSIONS: Over 95% of the population eligible for the pharmacological treatment of hypercholesterolaemia was either untreated or was uncontrolled. To decrease undertreatment, identification of high-risk patients should be increased. Those who are treated with lipid-lowering medication could further benefit from more aggressive treatment, especially with statins. |
| author |
Mantel-Teeuwisse, A K Verschuren, W M M Klungel, O H Kromhout, D Lindemans, A D Avorn, J Porsius, A J de Boer, A |
| author_facet |
Mantel-Teeuwisse, A K Verschuren, W M M Klungel, O H Kromhout, D Lindemans, A D Avorn, J Porsius, A J de Boer, A |
| author_sort |
Mantel-Teeuwisse, A K |
| title |
Undertreatment of hypercholesterolaemia: a population-based study |
| title_short |
Undertreatment of hypercholesterolaemia: a population-based study |
| title_full |
Undertreatment of hypercholesterolaemia: a population-based study |
| title_fullStr |
Undertreatment of hypercholesterolaemia: a population-based study |
| title_full_unstemmed |
Undertreatment of hypercholesterolaemia: a population-based study |
| title_sort |
undertreatment of hypercholesterolaemia: a population-based study |
| publisher |
Blackwell Science Inc |
| publishDate |
2003 |
| url |
https://ncbi.nlm.nih.gov/pmc/articles/PMC1884230/ https://ncbi.nlm.nih.gov/pubmed/12680888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2003.01769.x |
| _version_ |
1748208717722025984 |